Detailed Information on Publication Record
2012
Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice
JUŘICA, Jan, Richard BARTEČEK, Alexandra ŽOURKOVÁ, Eva PINDUROVÁ, Alexandra ŠULCOVÁ et. al.Basic information
Original name
Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice
Authors
JUŘICA, Jan (203 Czech Republic, belonging to the institution), Richard BARTEČEK (203 Czech Republic, belonging to the institution), Alexandra ŽOURKOVÁ (203 Czech Republic, belonging to the institution), Eva PINDUROVÁ (203 Czech Republic, belonging to the institution), Alexandra ŠULCOVÁ (203 Czech Republic, guarantor, belonging to the institution), Tomáš KAŠPÁREK (203 Czech Republic, belonging to the institution) and Ondřej ZENDULKA (203 Czech Republic, belonging to the institution)
Edition
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, HOBOKEN, WILEY-BLACKWELL, 2012, 0269-4727
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30104 Pharmacology and pharmacy
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.104
RIV identification code
RIV/00216224:14740/12:00060574
Organization unit
Central European Institute of Technology
UT WoS
000305894800020
Keywords in English
CYP2D6; dextromethorphan; genotype; metabolic ratio; phenotype; serum
Tags
International impact, Reviewed
Změněno: 8/4/2013 11:02, Olga Křížová
Abstract
V originále
What is known and Objective: Accurate prediction of actual CYP2D6 metabolic activity may prevent some adverse drug reactions and improve therapeutic response in patients receiving CYP2D6 substrates. Dextromethorphan-to-dextrorphan metabolic ratio (MRDEM/DOR) is well established as a marker of CYP2D6 metabolizer status. The relationship between urine and plasma or serum MRDEM/DOR is not well established nor is there evidence of antimode for separation of intermediate and especially poor metabolizers (PM) from extensive metabolizers (EM). This study addressed whether CYP2D6 phenotyping using molar metabolic ratio of dextromethorphan to dextrorphan (MRDEM/DOR) in serum is usable and reliable in clinical practice as urinary MRDEM/DOR. Methods: We measured MRDEM/DOR in serum and CYP2D6 genotype in 51 drug-naive patients and 30 volunteers. Receiver-operator characteristic (ROC) analysis was used for the evaluation of optimum cut-off value for discriminating between extensive, intermediate and PM. In addition, we studied the correlation of serum MRDEM/DOR with urine MRDEM/DOR in the 30 healthy volunteers. Results and Discussion: A trimodal distribution of log MRDEM/DOR in serum was observed, with substantial overlap between extensive and intermediate metabolizer groups. We obtained an acceptable cut-off serum MRDEM/DOR value to discriminate between PM and either extensive or extensive + intermediate metabolizers. Using serum MRDEM/DOR, it seems to be unreliable to discriminate EM from intermediate metabolizers (IM). A strong correlation between serum MRDEM/DOR and urine MRDEM/DOR was found. What is new and Conclusion: Serum MRDEM/DOR (3 h) correlated with MRDEM/DOR in urine (08 h). Serum MRDEM/DOR discriminated between extensive and PM and between extensive + intermediate and PM. Our CYP2D6 phenotyping using serum dextromethorphan/dextrorphan molar ratio appears reliable but requires independent validation.
Links
| ED1.1.00/02.0068, research and development project |
| ||
| NS9676, research and development project |
|